ClinicalTrials.gg
CompletedNCT06195839BENEFIT-HUpdated Nov 13, 2026Results posted

Building Engagement Using Financial Incentives Trial - Hypertension

An interventional study of Remote Patient Monitoring and Self-monitoring of hypertension-related factors in Hypertension, Health Behavior and Healthcare Patient Acceptance, sponsored by Tulane University. Completed at 2 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Tulane University · Not applicable, Interventional, and Health services research

How we know

Updated Nov 13, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Hypertension by Tulane University — 2 open to participants now, 7 under way, none of them phase 3. Hypertension · Tulane University.

Enrollment
13th of 15
50 · median 1,176
Started
2024
the only one that year
No phase
13 of 17
2 open now
Registered
16th of 17
by date

Among the 17 studies in Hypertension by Tulane University, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 13 with no phase, and was the 16th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 17 studies in Hypertension by Tulane University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hypertension by Tulane University, or all of them as a file.
02

Study summary

The goal of this pilot clinical trial is to determine feasibility and explore whether immediate versus delayed patient financial incentives improve patient engagement with self-monitoring of blood pressure in patients with uncontrolled hypertension at Louisiana federally qualified health centers (FQHCs). The main questions it aims to answer are:

  • Do patients randomized to receive financial incentives on a weekly basis during the study (immediate) have better adherence to blood pressure self-monitoring compared to patients randomized to receive financial incentives at the end of the study (delayed)?
  • Do patients randomized to immediate financial incentives have better blood pressure control compared to patients randomized to delayed incentives?

Participants will:

  • attend a baseline visit to measure blood pressure, respond to a baseline survey, and receive remote patient monitoring devices and instructions to take home with them (home blood pressure monitor, wrist-worn sensor to track sleep activity, and associated apps)
  • receive a random allocation to one of two groups: control condition (receive cash incentives at the end of the study for measuring blood pressure as instructed) or intervention condition (receive weekly cash incentives throughout the study for measuring blood pressure as instructed)
  • use remote patient monitoring devices during a two month study period, receive weekly reports on adherence to blood pressure monitoring, and receive weekly financial incentives (intervention condition only)
  • attend one follow-up visit at 2 months to measure their blood pressure, complete a follow-up survey, return the remote patient monitoring devices, and receive financial incentives for blood pressure monitoring (control condition only)

Researchers will compare the immediate and delayed incentive groups to see if there are differences in blood pressure monitoring adherence rates and blood pressure control.

03

Conditions studied

  • Hypertension
  • Health Behavior
  • Healthcare Patient Acceptance
  • Patient Engagement
  • Adherence, Patient

Keywords

  • preventive healthcare
  • patient financial incentives
  • federally qualified health center (FQHC)
  • remote patient monitoring (RPM)
  • health services
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥40 years
  • receive care at a participating FQHC
  • taking blood pressure medication
  • uncontrolled blood pressure at most recent clinic visit (systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥80 mm Hg)
  • ability to understand and speak English
  • able to access a smartphone

Exclusion criteria

Exclusion Criteria:

  • currently participating in another clinical trial or research study on blood pressure, medication-taking, or sleep
  • unable or unwilling to give
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Immediate Financial Incentives for BP monitoring

    * instructions for participating in a 2-month remote patient monitoring program * home blood pressure monitor and associated smartphone app, which includes a module for logging medication-taking * wrist-worn sensor and associated smartphone app * weekly adherence feedback to home blood pressure monitoring * immediate financial incentives for home blood pressure monitoring distributed weekly

    Behavioral: Remote Patient Monitoring · Behavioral: Self-monitoring of hypertension-related factors · Behavioral: Immediate financial incentives

  • Active comparator
    Delayed Financial Incentives for BP monitoring

    * instructions for participating in a 2-month remote patient monitoring program * home blood pressure monitor and associated smartphone app, which includes a module for logging medication-taking * wrist-worn sensor and associated smartphone app * weekly adherence feedback to home blood pressure monitoring * delayed financial incentives for home blood pressure monitoring distributed at the end of the study

    Behavioral: Remote Patient Monitoring · Behavioral: Self-monitoring of hypertension-related factors · Behavioral: Delayed financial incentives

Interventions

  • BehavioralRemote Patient Monitoring

    Participants will be given a home blood pressure machine and instructed to take their blood pressure twice/day (once in the morning and once at night) for the duration of the 2-month study. Blood pressure values will be immediately available in their patient-facing portal accessible via smartphone app, and patients will receive weekly feedback reports on their adherence to the home blood pressure monitoring protocol. Patients' blood pressure values will also be accessible to their clinical care team via an administrator portal, which will alert clinicians of any values above or below pre-specified clinical thresholds.

  • BehavioralSelf-monitoring of hypertension-related factors

    As part of self-monitoring of hypertension-related factors, the blood pressure monitoring patient-facing app will also prompt patients daily to report whether or not they took their blood pressure medication. in addition, participants will be provided with a wrist-worn sensor and instructed to wear it at night to track their sleep activity. Data on sleep activity will be available to patients through a separate patient-facing app accessible on their smartphone.

  • BehavioralImmediate financial incentives

    Weekly financial incentives for measuring their blood pressure as instructed (up to $25/week: $5/day for up to 5 days/week)

  • BehavioralDelayed financial incentives

    Financial incentives for measuring their blood pressure as instructed in one payment at the end of the study (up to $25/week: $5/day for up to 5 days/week)

06

What researchers measure

Primary outcomes

  1. Between-group Difference in Weekly Adherence to Blood Pressure Monitoring

    Weekly adherence to blood pressure monitoring will be defined as the number of days that the participant used the home blood pressure monitor at least once, captured in the blood pressure monitoring app usage data. For each week of their monitoring period, the number of days that a participant had at least one blood pressure measurement will be calculated (0-7 days). Participants' weekly adherence scores will then be averaged over the 8-week monitoring period into a single aggregate score capturing their average weekly adherence to blood pressure monitoring.

    Time frame: 8 weeks

Secondary outcomes

  1. Between-group Mean Difference in Change in Systolic Blood Pressure

    Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Change in systolic blood pressure (SBP) will be calculated as participants' SBP value at the 8-week follow-up visit minus their SBP value at the baseline visit.

    Time frame: baseline, 8 weeks

  2. Between-group Mean Difference in Change in Diastolic Blood Pressure

    Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Change in diastolic blood pressure (DBP) will be calculated as participants' DBP value at the 8-week follow-up visit minus their DBP value at the baseline visit.

    Time frame: baseline, 8 weeks

  3. Between-group Difference in the Percentage of Participants With Blood Pressure Control (<130/80 mm Hg)

    Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Blood pressure control will be defined as systolic \<130 mm Hg and diastolic \<80 mm Hg.

    Time frame: 8 weeks

  4. Between-group Difference in the Percentage of Participants With Systolic Blood Pressure Control (<130 mm Hg)

    Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Systolic blood pressure control will be defined as systolic \<130 mm Hg.

    Time frame: 8 weeks

Other outcomes

  1. Number of Patients Reached for Recruitment

    Number of patients with whom the study team connected by phone or who participated in a recruitment conversation in clinic

    Time frame: 3 months

  2. Number of Patients Assessed for Eligibility

    Number of patients who begin eligibility screener

    Time frame: 3 months

  3. Number of Patients Enrolled

    Number of patients who consent and are randomized

    Time frame: 3 months

  4. Percentage of Intended Intervention Received

    The total amount of financial incentives delivered to each participant during the blood pressure monitoring period will be calculated, then divided by the total possible financial incentive amount to represent each participant's percentage of possible financial incentives received. Mean scores in each study arm will be reported as a measure of the percentage of the intended financial incentive intervention that was received by participants in each group.

    Time frame: 2 months

07

Results

Posted Nov 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneImmediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP Monitoring
Started2525
Completed2424
Not completed11

Outcome measures

PrimaryBetween-group Difference in Weekly Adherence to Blood Pressure Monitoring

Weekly adherence to blood pressure monitoring will be defined as the number of days that the participant used the home blood pressure monitor at least once, captured in the blood pressure monitoring app usage data. For each week of their monitoring period, the number of days that a participant had at least one blood pressure measurement will be calculated (0-7 days). Participants' weekly adherence scores will then be averaged over the 8-week monitoring period into a single aggregate score capturing their average weekly adherence to blood pressure monitoring.

Time frame:
8 weeks
Reported as:
Mean · Days per week
Between-group Difference in Weekly Adherence to Blood Pressure Monitoring
Days per weekImmediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP Monitoring
Between-group Difference in Weekly Adherence to Blood Pressure Monitoring5.11 ± 2.115.73 ± 1.90
SecondaryBetween-group Mean Difference in Change in Systolic Blood Pressure

Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Change in systolic blood pressure (SBP) will be calculated as participants' SBP value at the 8-week follow-up visit minus their SBP value at the baseline visit.

Time frame:
baseline, 8 weeks
Reported as:
Mean · mmHg
Between-group Mean Difference in Change in Systolic Blood Pressure
mmHgImmediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP Monitoring
Between-group Mean Difference in Change in Systolic Blood Pressure-2.40 ± 17.89-9.49 ± 26.29
SecondaryBetween-group Mean Difference in Change in Diastolic Blood Pressure

Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Change in diastolic blood pressure (DBP) will be calculated as participants' DBP value at the 8-week follow-up visit minus their DBP value at the baseline visit.

Time frame:
baseline, 8 weeks
Reported as:
Mean · mmHg
Between-group Mean Difference in Change in Diastolic Blood Pressure
mmHgImmediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP Monitoring
Between-group Mean Difference in Change in Diastolic Blood Pressure-0.94 ± 11.95-5.11 ± 14.30
SecondaryBetween-group Difference in the Percentage of Participants With Blood Pressure Control (<130/80 mm Hg)

Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Blood pressure control will be defined as systolic \<130 mm Hg and diastolic \<80 mm Hg.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Between-group Difference in the Percentage of Participants With Blood Pressure Control (<130/80 mm Hg)
ParticipantsImmediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP Monitoring
Between-group Difference in the Percentage of Participants With Blood Pressure Control (<130/80 mm Hg)106
SecondaryBetween-group Difference in the Percentage of Participants With Systolic Blood Pressure Control (<130 mm Hg)

Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Systolic blood pressure control will be defined as systolic \<130 mm Hg.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Between-group Difference in the Percentage of Participants With Systolic Blood Pressure Control (<130 mm Hg)
ParticipantsImmediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP Monitoring
Between-group Difference in the Percentage of Participants With Systolic Blood Pressure Control (<130 mm Hg)139
Other pre-specifiedNumber of Patients Reached for Recruitment

Number of patients with whom the study team connected by phone or who participated in a recruitment conversation in clinic

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Patients Reached for Recruitment
ParticipantsRecruitment Sample
Number of Patients Reached for Recruitment107
Other pre-specifiedNumber of Patients Assessed for Eligibility

Number of patients who begin eligibility screener

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Patients Assessed for Eligibility
ParticipantsReachable Sample
Number of Patients Assessed for Eligibility77
Other pre-specifiedNumber of Patients Enrolled

Number of patients who consent and are randomized

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Patients Enrolled
ParticipantsEligible Sample
Number of Patients Enrolled50
Other pre-specifiedPercentage of Intended Intervention Received

The total amount of financial incentives delivered to each participant during the blood pressure monitoring period will be calculated, then divided by the total possible financial incentive amount to represent each participant's percentage of possible financial incentives received. Mean scores in each study arm will be reported as a measure of the percentage of the intended financial incentive intervention that was received by participants in each group.

Time frame:
2 months
Reported as:
Mean · percentage of total possible incentives
Percentage of Intended Intervention Received
percentage of total possible incentivesImmediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP Monitoring
Percentage of Intended Intervention Received79.60 ± 30.3787.30 ± 26.17

Adverse events

Collected over Two months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immediate Financial Incentives for BP Monitoring0/24 (0%)2/24 (8.3%)1/24 (4.2%)
Delayed Financial Incentives for BP Monitoring0/24 (0%)0/24 (0%)1/24 (4.2%)
Most frequent serious events
Most frequent serious events
EventImmediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP Monitoring
Hospitalization due to food poisoningInfections and infestations1/240/24
Hospitalization due to motor vehicle accidentInjury, poisoning and procedural complications1/240/24
Most frequent other events
Most frequent other events
EventImmediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP Monitoring
ED visit due to dizzinessNervous system disorders1/241/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)Immediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP MonitoringTotal
Mean56.32 ± 10.0459.08 ± 9.1457.70 ± 9.60
Sex: Female, Male
Sex: Female, Male(Participants)Immediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP MonitoringTotal
Female161632
Male9918
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Immediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP MonitoringTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American232043
White156
More than one race000
Unknown or Not Reported101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Immediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP MonitoringTotal
Hispanic or Latino101
Not Hispanic or Latino202242
Unknown or Not Reported437
Region of Enrollment
Region of Enrollment(Participants)Immediate Financial Incentives for BP MonitoringDelayed Financial Incentives for BP MonitoringTotal
United States252550
08

Study locations

2 sites
  • CommuniHealth Services
    Bastrop, Louisiana 71220, United States
  • David Raines Community Health Center
    Shreveport, Louisiana 71107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Sep 2025, 15 months.

Results were first posted in Nov 2026, 1 year 2 months after primary completion.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 15 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 8, 2024
StartActual
May 22, 2024
Primary completionActual
Sep 11, 2025
CompletionActual
Sep 11, 2025
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedBetween-group differenceDifference in weekly adherenceWeekly Adherence to blood pressure monitoringBlood Pressure MonitoringTime frame: 8 weeks
Nov 13, 2026
Documents
Secondary outcomes
8 edited
What changed in the outcomes
  • EditedBetween-group mean differenceMean Difference in changeChange in systolic blood pressureSystolic Blood PressureTime frame: 8 weeks → baseline, 8 weeks
  • EditedBetween-group mean differenceMean Difference in changeChange in diastolic blood pressureDiastolic Blood PressureTime frame: 8 weeks → baseline, 8 weeks
  • EditedBetween-group differenceDifference in the proportion with blood pressure controlPercentage of Participants With Blood Pressure Control (<130/80 mm Hg)Time frame: 8 weeks
  • EditedBetween-group differenceDifference in the proportion with systolic blood pressure controlPercentage of Participants With Systolic Blood Pressure Control (<130 mm Hg)Time frame: 8 weeks
  • Editedother outcomeNumber of patient approachedPatients Reached for recruitmentRecruitmentTime frame: 3 months
  • Editedother outcomeNumber of patients assessedPatients Assessed for eligibilityEligibilityTime frame: 3 months
  • Editedother outcomeNumber of patients enrolledPatients EnrolledTime frame: 3 months
  • Changedother outcomeBefore Number of patients who receive intended treatmentNow Percentage of Intended Intervention ReceivedTime frame: 2 months
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedBetween-group differenceDifference in weekly adherenceWeekly Adherence to blood pressure monitoringBlood Pressure MonitoringTime frame: 8 weeks
    Secondary outcomes 8 edited
    What changed in the outcomes
    • EditedBetween-group mean differenceMean Difference in changeChange in systolic blood pressureSystolic Blood PressureTime frame: 8 weeks → baseline, 8 weeks
    • EditedBetween-group mean differenceMean Difference in changeChange in diastolic blood pressureDiastolic Blood PressureTime frame: 8 weeks → baseline, 8 weeks
    • EditedBetween-group differenceDifference in the proportion with blood pressure controlPercentage of Participants With Blood Pressure Control (<130/80 mm Hg)Time frame: 8 weeks
    • EditedBetween-group differenceDifference in the proportion with systolic blood pressure controlPercentage of Participants With Systolic Blood Pressure Control (<130 mm Hg)Time frame: 8 weeks
    • Editedother outcomeNumber of patient approachedPatients Reached for recruitmentRecruitmentTime frame: 3 months
    • Editedother outcomeNumber of patients assessedPatients Assessed for eligibilityEligibilityTime frame: 3 months
    • Editedother outcomeNumber of patients enrolledPatients EnrolledTime frame: 3 months
    • Changedother outcomeBefore Number of patients who receive intended treatmentNow Percentage of Intended Intervention ReceivedTime frame: 2 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06195839
Lead sponsor
Tulane University
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
May 22, 2024
Primary completion
Sep 11, 2025
Completion
Sep 11, 2025
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Study contacts

Marie Krousel-Wood, MD, MSPH
principal investigator · Tulane University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion